44 results
SC TO-T/A
Swedish Orphpan Biovitrum AB
13 Jun 23
Third party tender offer statement (amended)
7:01am
paragraph immediately after the last paragraph of such subsection with the caption “Antitrust Compliance – HSR Act:”
“Each of CTI BioPharma and Sobi filed … a Premerger Notification and Report Form under the HSR Act with the FTC and the Antitrust Division in connection with the purchase of Shares
SC 14D9/A
CTIC
CTI BioPharma Corp
12 Jun 23
Tender offer solicitation (amended)
6:06am
“Regulatory Approvals—Antitrust in the United States”:
“Under the HSR Act, the purchase of Shares in the Offer may not be completed until the expiration … and the Merger with the FTC and the Antitrust Division, unless the waiting period is earlier terminated by the FTC and the Antitrust Division. If the 15th
SC 14D9
CTIC
CTI BioPharma Corp
25 May 23
Tender offer solicitation
7:00am
-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”); and (iv) those other conditions set forth in Annex I to the Merger Agreement … (and any extension thereof) applicable to the consummation of the Offer under the HSR Act or any foreign antitrust or competition-related legal
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
waiting period applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended. The Offer is also subject
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
) prior to the expiration of the Offer, the expiration or termination of any waiting period applicable to the Offer under the Hart-Scott-Rodino Antitrust
SC TO-T
EX-99
5bbx7l
25 May 23
Third party tender offer statement
6:46am
SC TO-T
EX-99
pn50m7l8
25 May 23
Third party tender offer statement
6:46am
SC TO-T
EX-99
dj72ryf96s
25 May 23
Third party tender offer statement
6:46am
SC TO-C
EX-99.1
ztooz10rpf6tvwp9
10 May 23
Information about tender offer
5:01pm
SC14D9C
jmeym2rb5kx7vv0ob
10 May 23
Written communication relating to third party tender offer
1:30pm
SC14D9C
EX-2.1
s3mpm1qb
10 May 23
Written communication relating to third party tender offer
1:30pm
SC14D9C
EX-99.2
0zqjikej6 tt
10 May 23
Written communication relating to third party tender offer
1:30pm
8-K
jsxfj 2ngvdp2s1
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-99.2
vvxsjg2zavejjmjic
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-2.1
jrvvh0f
10 May 23
Tender and Support Agreement
8:05am
8-K
2wy1m 7q91h6
22 Mar 11
Other Events
12:00am
8-K
32q25d7d8os7awy0215h
14 Mar 11
Phase III Pivotal Trial in Acute Myeloid Leukemia Expected to Start in Q4 2011
12:00am
8-K
EX-99.1
o5w 1wgny63qo
30 Sep 09
Regulation FD Disclosure
12:00am